Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
Wysong A, Somani AK, Ibrahim SF, Cañueto J, Fitzgerald AL, Siegel JJ, Prasai A, Goldberg MS, Farberg AS, Regula C, Bar A, Kasprzak J, Brodland DG, Koyfman SA, Arron ST. Wysong A, et al. Among authors: fitzgerald al. Dermatol Ther (Heidelb). 2024 Mar;14(3):593-612. doi: 10.1007/s13555-024-01111-5. Epub 2024 Mar 1. Dermatol Ther (Heidelb). 2024. PMID: 38424384 Free PMC article.
Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test.
Ibrahim SF, Kasprzak JM, Hall MA, Fitzgerald AL, Siegel JJ, Kurley SJ, Covington KR, Goldberg MS, Farberg AS, Trotter SC, Reed K, Brodland DG, Koyfman SA, Somani AK, Arron ST, Wysong A. Ibrahim SF, et al. Among authors: fitzgerald al. Future Oncol. 2022 Mar;18(7):833-847. doi: 10.2217/fon-2021-1277. Epub 2021 Nov 25. Future Oncol. 2022. PMID: 34821148 Free article.
Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test for Improved Patient Management Decisions and Disease-Related Outcomes when Combined with Current Clinicopathological Risk Factors for Cutaneous Squamous Cell Carcinoma (cSCC): Case Series.
Au JH, Hooper PB, Fitzgerald AL, Somani AK. Au JH, et al. Among authors: fitzgerald al. Dermatol Ther (Heidelb). 2022 Feb;12(2):591-597. doi: 10.1007/s13555-021-00665-y. Epub 2021 Dec 23. Dermatol Ther (Heidelb). 2022. PMID: 34951694 Free PMC article.
Analytical validity of DecisionDx-SCC, a gene expression profile test to identify risk of metastasis in cutaneous squamous cell carcinoma (SCC) patients.
Borman S, Wilkinson J, Meldi-Sholl L, Johnson C, Carter K, Covington KR, Fitzgerald AL, Kurley SJ, Farberg AS, Goldberg MS, Monzon FA, Oelschlager K, Cook RW. Borman S, et al. Among authors: fitzgerald al. Diagn Pathol. 2022 Feb 25;17(1):32. doi: 10.1186/s13000-022-01211-w. Diagn Pathol. 2022. PMID: 35216597 Free PMC article.
Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
Hooper PB, Farberg AS, Fitzgerald AL, Siegel JJ, Rackley BB, Prasai A, Kurley SJ, Goldberg MS, Litchman GH. Hooper PB, et al. Among authors: fitzgerald al. Cancer Invest. 2022 Nov;40(10):911-922. doi: 10.1080/07357907.2022.2116454. Epub 2022 Sep 15. Cancer Invest. 2022. PMID: 36073945 Free article.
32 results